XTX Topco Ltd Sells 1,333 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

XTX Topco Ltd lowered its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 24.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 4,083 shares of the medical instruments supplier’s stock after selling 1,333 shares during the quarter. XTX Topco Ltd’s holdings in West Pharmaceutical Services were worth $1,345,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Avantax Advisory Services Inc. acquired a new position in shares of West Pharmaceutical Services during the fourth quarter valued at about $288,000. UBS Group AG increased its position in West Pharmaceutical Services by 15.8% in the 4th quarter. UBS Group AG now owns 82,290 shares of the medical instruments supplier’s stock valued at $28,976,000 after buying an additional 11,245 shares in the last quarter. Clearbridge Investments LLC acquired a new position in West Pharmaceutical Services during the 4th quarter worth approximately $1,572,000. Quest Partners LLC bought a new position in West Pharmaceutical Services in the fourth quarter worth approximately $545,000. Finally, Assetmark Inc. grew its stake in West Pharmaceutical Services by 40.4% in the fourth quarter. Assetmark Inc. now owns 3,650 shares of the medical instruments supplier’s stock valued at $1,285,000 after acquiring an additional 1,050 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Down 1.0 %

NYSE WST opened at $308.15 on Friday. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $413.70. The business has a 50 day moving average price of $303.67 and a 200-day moving average price of $337.77. The company has a market cap of $22.45 billion, a price-to-earnings ratio of 40.65, a P/E/G ratio of 10.58 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. During the same quarter last year, the firm posted $2.11 EPS. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. As a group, equities analysts expect that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.